The U.S. Department of Health and Human Services (HHS) is once again considering a delay in the implementation date for a final rule on 340B prescription drug ceiling price provisions and the $5,000 civil monetary penalties for manufacturers that overcharge safety net health care providers for covered outpatient drugs.